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The prognosis of chronic lymphocytic leukemia (CLL) depends on
different markers, including cytogenetic aberrations, oncogenic
mutations, and mutational status of the immunoglobulin (Ig)
heavy-chain variable (IGHV) gene. The number of IGHV mutations
distinguishes mutated (M) CLL with a markedly superior prognosis
from unmutated (UM) CLL cases. In addition, B cell antigen receptor
(BCR) stereotypes as defined by IGHV usage and complementaritydetermining regions (CDRs) classify ∼30% of CLL cases into prognostically important subsets. Subset 2 expresses a BCR with the
combination of IGHV3-21–derived heavy chains (HCs) with IGLV321–derived light chains (LCs), and is associated with an unfavorable prognosis. Importantly, the subset 2 LC carries a single-point
mutation, termed R110, at the junction between the variable and
constant LC regions. By analyzing 4 independent clinical cohorts
through BCR sequencing and by immunophenotyping with antibodies specifically recognizing wild-type IGLV3-21 and R110-mutated
IGLV3-21 (IGLV3-21R110), we show that IGLV3-21R110–expressing
CLL represents a distinct subset with poor prognosis independent
of IGHV mutations. Compared with other alleles, only IGLV3-21*01
facilitates effective homotypic BCR–BCR interaction that results in
autonomous, oncogenic BCR signaling after acquiring R110 as a
single-point mutation. Presumably, this mutation acts as a standalone driver that transforms IGLV3-21*01–expressing B cells to
develop CLL. Thus, we propose to expand the conventional definition of CLL subset 2 to subset 2L by including all IGLV3-21R110–
expressing CLL cases regardless of IGHV mutational status. Moreover, the generation of monoclonal antibodies recognizing IGLV3-21
or mutated IGLV3-21R110 facilitates the recognition of B cells carrying
this mutation in CLL patients or healthy donors.
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he most prevalent form of leukemia among adults in the
Western world, namely chronic lymphocytic leukemia (CLL),
originates from an indolent type of clonal expansion of B cells (1,
2). About 80% of all CLL cases are diagnosed in patients >60 y
old (3). The clinical course of CLL varies widely and is associated
with distinct recurrent cytogenetic aberrations, gene mutations,
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and sequence characteristics of the clonal B cell antigen receptor
(BCR) expressed by CLL cells (4–12). Specifically, the sequence
homology of the immunoglobulin (Ig) heavy-chain variable (IGHV)
segment of the BCR heavy chain (HC) to its most closely related
germline IGHV segment has been identified empirically as an
important prognostic parameter. A categorical cutoff of 98%
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Results and Discussion
Monoclonal Antibodies Reveal a High Frequency of IGLV3-21R110. We

generated 2 highly specific monoclonal antibodies to characterize wild-type (wt) IGLV3-21 and mutated IGLV3-21R110 LC
expression in primary CLL samples (Fig. 1A and SI Appendix,
Fig. S1 A and B). One recognizes IGLV3-21 variants irrespective
of the R110 mutation and is referred to as anti-wt IGLV3-21
(anti-wt) while the other specifically recognizes the mutated
IGLV3-21R110 and is referred to as anti–IGLV3-21R110 (antiR110). Subsequently, we performed immunophenotyping and
determined the frequency of the IGLV3-21R110 LC as compared
with IGLV3-21 (Fig. 1A and SI Appendix, Fig. S1B) in analysis
cohort (AC) I consisting of 154 CLL patients, of which complete
informative follow-up data and mutational analyses were available for 122 cases (SI Appendix, Tables S1–S6). By analyzing the
entire AC I (N = 154), we found 34 CLL samples (22.08%) that
express IGLV3-21 (Fig. 1B). The majority (27 of 34, or 17.53%)
of these IGLV3-21 CLL samples possessed an IGLV3-21R110
Maity et al.
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Fig. 1. Rapid identification of light-chain IGLV3-21 and IGLV3-21R110 from CLL
cases. (A) Exemplary immunophenotyping histograms to detect wild-type and
mutated light chains derived from the IGLV3-21 segment in a CLL subset 2 (LS
#42), a UM-CLL (LS #17), and an M-CLL (LS #151) case. Commonly, CLL subset 2
is associated with IGLV3-21–derived LCs carrying R110 as a single-point mutation at the variable–constant region junction. The R110 mutation is referred
to as IGLV3-21R110. The antibodies recognize wt IGLV3-21 variants and the
mutated IGLV3-21R110 and are referred to as anti-wt IGLV3-21 and anti–IGLV321R110, respectively. The expressed IGHV and IGLV alleles and their mutational
statuses are indicated alongside. Histograms (red line) show the expression of
IGLV3-21 and IGLV3-21R110 using fluorescently labeled anti-wt and anti-R110
antibodies, respectively. The plotted cells are pregated for CLL population by
CD19 and CD5 expression after excluding dead cells. The control (gray-filled)
CLL sample expresses a non–IGLV3-21 LC. Median fluorescence intensities of
anti-wt and anti-R110 binding are indicated within the plots. (B) Pie chart of
the immunophenotyping results depicting the proportion of IGLV3-21– (green)
and IGLV3-21R110– (red) positive cases in a CLL cohort (n = 154). (C) Pie chart of
IGLV/IGKV sequencing results within the same CLL cohort (n = 147), revealing
the frequency of IGLV3-21 (green), IGLV3-21R110 (red) including CLL subset 2
(dashed area), as well as other IGLVs (gray) and IGKVs (white). (D) Scatterplot of
the IGHV mutational status of 147 CLL cases having sequence results grouped
by different IGLV segments as follows: IGLV3-21R110 cases (orange), IGLV3-21
cases (green), and others (gray). The subset 2 CLL cases (black) are depicted
within IGLV3-21R110–positive cases. The dashed line indicates the conventional
98% cutoff of IGHV sequence homology to its germline variant that distinguishes UM- and M-CLL cases. While <98% IGHV sequence homology defines
an M-CLL case, ≥98% IGHV sequence homology defines an aggressive UMCLL case. (E ) Bar graph of relative AICDA expression (AU) analyzed by qRTPCR of IGLV3-21R110–negative (black) and IGLV3-21R110–positive (orange)
cases, both of which are subgrouped into UM- (open bars) and M-CLL
(gray-filled) cases according to IGHV mutational status, and compared
with healthy donor (blue) samples by using the 2-tailed Mann–Whitney U
test. The plot depicts a median bar along with the individual sample values, and the numbers of samples per group are depicted below. ns, nonsignificant; **P < 0.01.

LC, whereas only 7 (4.55%) were negative for the anti-R110
staining (Fig. 1B).
In parallel, IGV gene sequencing of 147 cases (of 154 cases
from AC I) confirmed the distribution of IGLV3-21 and IGLV321R110 as determined by immunophenotyping (Fig. 1C and SI
Appendix, Fig. S1C). The sequence analysis also revealed that
PNAS | February 25, 2020 | vol. 117 | no. 8 | 4321
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sequence homology of the CLL IGHV to its germline variant
distinguishes the so-called unmutated (UM) and mutated (M)
CLL cases. The UM-CLL cases have a strikingly inferior prognosis
compared with M-CLL (4, 5). In addition, an important role for
the BCR in CLL pathogenesis and aggressiveness is suggested
by the observation that ∼30% of all CLL cases, predominantly
UM-CLL, can be grouped into so-called BCR stereotypes (13, 14).
These stereotypes, also referred to as CLL subsets, are defined by
similarities in the BCR HC sequence, specifically by particular
IGHV and Ig heavy chain junctional (IGHJ) genes and the
complementarity-determining region (CDR)3 sequence created
by variable, diversity, and junctional (VDJ) recombination (13, 15,
16). Moreover, each of these subsets is associated with a distinctive
clinical course (13–15, 17). Thus, both M-/UM-CLL and subset
classifications serve as important markers for disease prognosis.
However, this classification requires extensive sequence characterization after initial clinical identification. For example, CLL
subset 2 is defined by a BCR HC composed of the IGHV3-21 and
IGHJ6 genes with a relatively short CDR3 of 9 amino acids (13).
Even though CLL subset 2 cases are mostly identified as M-CLL,
they are associated with a poor prognosis similar to UM-CLL
cases (13, 17). Additionally, CLL subset 2 is also known to express a light chain (LC) of the lambda isotype that utilizes the
IGLV3-21 gene. Expression of IGLV3-21 has also been associated
with poor prognosis of CLL (18), although no mechanistic explanation of this observation has been provided (14).
Our group has identified antigen-independent, autonomous
BCR signaling as the mechanistic basis for the pathogenic role of
the BCR in virtually all cases of CLL (19). Subsequently, exemplary structural crystallographic analyses for CLL subsets 2 and 4
have revealed homotypic interactions between BCR heterodimers
as the mechanistic basis for this BCR activation (20). Most importantly, the indispensable R110 residue for this homotypic
BCR–BCR interaction originates through nonsynonymous somatic hypermutation (SHM) of the germline G110 residue in the
IGLJ segment, and reversion of R110 into G110 abrogates autonomous BCR signaling (20).
Here we report comprehensive characterization of CLL and
healthy B cells expressing the R110-mutated IGLV3-21 LC
(termed IGLV3-21R110) by extensive BCR sequencing, development of IGLV3-21– and IGLV3-21R110–specific antibodies,
and mass cytometry analyses. We demonstrate the poor prognosis of IGLV3-21R110–expressing CLL and propose to replace
the conventionally defined CLL subset 2 with this “subset 2L.”
With 8 to 18% of CLL cases among different cohorts, subset 2L
is a CLL subset defined by functional immunology and represents the largest CLL subset recognized so far. Finally, we
identify the IGLV3-21*01 allele as an inherited risk factor to
develop CLL subset 2L.

AICDA independent of M-CLL or UM-CLL classification (Fig.
1E), it is conceivable that these CLL cases are heterogeneous
by IGLV3-21 sequence and might possess both unmutated
IGLV3-21 and mutated IGLV3-21R110 subpopulations. To exclude such subclonal variability, we performed single-cell HC
and LC sequencing on exemplary IGLV3-21– and IGLV321R110–expressing cases (Fig. 2). CLL samples were sorted by
fluorescence-activated cell sorting (FACS) (SI Appendix, Fig.
S2A), and the sorted cells were confirmed for IGLV3-21 and
IGLV3-21 R110 expression by anti-wt and anti-R110 staining,
4322 | www.pnas.org/cgi/doi/10.1073/pnas.1913810117

IGLV3-21R110 Defines a Clinically Aggressive CLL Phenotype. Next, we
investigated whether IGLV3-21R110 expression alone identified
CLL cases with poor prognosis irrespective of IGHV mutational
status or assignment to subset 2. Indeed, for those AC I cases
with sufficient outcome information (n = 122), the IGLV3-21R110–
expressing CLL patients required early treatment and had inferior
overall survival (OS) than IGLV3-21R110–negative M-CLL patients (Fig. 3 A and B). The required time to first treatment (TTFT)
of IGLV3-21R110–expressing CLL patients was very similar to
IGLV3-21R110–negative UM-CLL, and their OS was not significantly different. When IGLV3-21R110–expressing CLL patients were separated according to IGHV mutational status, both
TTFT and OS (Fig. 3 C and D) were virtually identical.
Despite the aggressive clinical course, the majority of IGLV321R110–expressing CLL cases from AC I carried the prognostically
favorable del13q14 genetic abnormality (21, 22), whereas the
unfavorable del17p or del11q22 genetic abnormality (12, 23)
occurred infrequently in CLL cases expressing IGLV3-21R110 (SI
Appendix, Table S2). Multivariable analysis confirmed the adverse
impact of IGLV3-21R110 on both clinical outcome parameters in
comparison with the remaining M-CLL (SI Appendix, Tables S3
and S4). In contrast, del17p lost its impact on OS upon multivariable analysis. Moreover, IGHV mutational status had no
prognostic relevance in IGLV3-21R110–expressing CLL since the
prognostic influence of the R110 mutation remained significant
when the IGLV3-21R110–expressing CLLs were split into IGHV
mutated and unmutated cases (SI Appendix, Tables S5 and S6).
With respect to genes recurrently mutated in CLL, targeted
sequencing of 100 B lymphoma-associated genes revealed
NOTCH1 mutations in IGLV3-21R110–expressing CLL at an
apparently similar frequency to published cases (Fisher’s exact
test: P = 0.52) (11). However, TP53 (P = 0.016), ATM (P = 0.008),
and SF3B1 (P < 0.0001) appeared to be more frequently mutated in IGLV3-21R110–expressing CLL (SI Appendix, Table S2).
IGLV3-21R110–expressing CLL also carried mutations in genes
encoding epigenetic modifiers such as CREBBP, KMT2D, and
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IGLV3-21 and IGLV3-21R110 CLLs Are Uniform by Single-Cell Sequence
Analysis. Since every IGLV3-21R110–expressing case expresses

respectively (SI Appendix, Fig. S2B) and plated as single cells. In
the subset 2 case, clonal homogeneity was indicated by LC sequences that almost exclusively carried the predicted IGLV321R110 sequence, and by expression of identical pairs of HC and
LC sequences. Similarly, the HC and LC identities of the IGLV3-21–
expressing CLL case were found to be uniform at the single-cell level.
Thus, the comprehensive sequencing result of the IGLV3-21–
and IGLV3-21R110–expressing cells within the respective CLL
cases confirms the clonal distribution of the R110 mutation
and emphasizes the specificities of the anti-wt and anti-R110
antibodies used for immunophenotyping.

percent of single cells

only 6 (4.08%) of the 27 IGLV3-21R110–expressing cases belonged
to stereotypic CLL subset 2 as defined by IGHV3-21 with a
characteristic CDR3 sequence (Fig. 1 C and D) (13, 18, 20).
Several other IGHV genes were found to be effectively pairing
with the IGLV3-21 LC (SI Appendix, Table S2), indicating that
CLL subset 2 represents a minor subgroup of IGLV3-21R110–
expressing CLL, while the majority have hitherto not been recognized as an immunobiologically related CLL subset. The homology
of all IGHV segments of the entire group of IGLV3-21R110–
expressing cases to their respective germline sequences varied
between 94.4 and 99.7% (Fig. 1D and SI Appendix, Table S2). In
contrast, the unmutated IGLV3-21–expressing cases were mostly
(3/4) the UM-CLL type based on a cutoff of 98% IGHV homology. Furthermore, the IGLV3-21R110–expressing cases predominantly expressed activation-induced cytidine deaminase
(AICDA), an enzyme initiating SHM (Fig. 1E). Since a single
IGLV3-21R110 mutation could theoretically represent the only
mutation required to initiate CLL development, acquisition of
additional Ig mutations is nonessential and could hence occur
to a variable degree. This scenario explains why IGLV3-21R110–
expressing CLL straddles the conventionally defined UM- and
M-CLL categories, although the origin of IGLV3-21R110–expressing
CLL biologically requires SHM (20). In contrast, the unmutated
IGLV3-21–expressing cases were mostly (3/4) a UM-CLL type
based on a cutoff of 98% IGHV homology (Fig. 1D and SI Appendix, Table S2).
To reduce possible sampling bias, we extended our study and
analyzed the additional AC II (SI Appendix, Table S7) consisting
of 134 CLL patients, all expressing the lambda light chain (IGL).
Immunophenotyping and sequencing analyses revealed that 23
and 10 CLL cases expressed mutated IGLV3-21R110 (17.16%)
and unmutated IGLV3-21 (7.46%), respectively (SI Appendix,
Fig. S1D). As expected, only 4 cases (4/23) were stereotypic CLL
subset 2, confirming the fact that CLL subset 2 represents a
minor subgroup of IGLV3-21R110–expressing CLL. The IGLV321R110–expressing cases remained uniformly distributed through
M- and UM-CLL classification according to IGHV identity (SI
Appendix, Fig. S1E and Table S8).
In contrast, the unmutated IGLV3-21–expressing cases were
predominantly (7/10) the UM-CLL type. Similarly, AC III, AC
IV, and AC V (SI Appendix, Tables S9–S12) confirmed the above
findings that IGLV3-21R110 CLL is found within M- and UM-CLL
and that IGLV3-21R110 is not restricted to CLL subset 2, as different
IGHV-derived HCs can pair with IGLV3-21R110 in CLL pathogenesis. Intriguingly, AC V, originating from the US population,
represents very high frequency IGLV3-21R110 (14 of 15) as well as
CLL subset 2 (13 of 15) cases (SI Appendix, Table S12). In contrast,
AC IV, originating from the Greek population, shows only 4 CLL
subset 2 patients among 14 identified IGLV3-21R110 cases (SI Appendix, Table S11). Perhaps this difference is attributable to the
prevalence of CLL subset 2 on different continents. Together, these
data show that IGLV3-21 is overrepresented in CLL and that most
cases present as mutated IGLV3-21R110 without belonging to CLL
subset 2.
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Fig. 2. Clonality of IGLV3-21R110 CLL cases at the single-cell level. Horizontal
bar graph of IGHV and IGLV allele usage determined by single-cell paired HC
and LC sequence analyses of 2 exemplary IGLV3-21 (green) and 2 exemplary
IGLV3-21R110 (orange) CLL cases. Numbers of analyzed single cells are individually depicted. The unique IGHV and IGLV genes and alleles for each
case are depicted inside the bars.
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Fig. 3. IGLV3-21R110 is associated with decreased TTFT and OS (AC I; n =
122). (A) Kaplan–Meier analysis for treatment-free survival from diagnosis of
IGLV3-21R110–positive CLL patients compared with IGLV3-21R110–negative
M-CLL and UM-CLL patients classified by IGHV identity. (B) Kaplan–Meier
analysis for overall survival of IGLV3-21R110–positive CLL patients compared
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analysis for treatment-free survival from diagnosis of IGLV3-21R110–positive
CLL patients according to IGHV mutational status. (D) Kaplan–Meier analysis
for OS from diagnosis of IGLV3-21R110–positive CLL patients according to
IGHV mutational status. All data are from AC I, and the depicted P values
were obtained from log-rank (Mantel–Cox) analyses.

EP300 (SI Appendix, Table S2) that are associated with oncogenesis of germinal center-type lymphomas (24–26).
Next, we analyzed another independent AC II consisting of
134 CLL patients expressing IGL (SI Appendix, Table S7) and
assessed the prognostic severity of IGLV3-21R110 (n = 23) cases
compared with IGLV3-21 (n = 10) cases (SI Appendix, Fig. S3A).
Indeed, the TTFT and OS of the IGLV3-21R110 CLL patients
were significantly shorter as compared with IGLV3-21 patients,
and the remaining IGLV patients (n = 102) remained intermediate between IGLV3-21R110 and IGLV3-21. The TTFT and OS
of these IGLV3-21R110 CLL patients (n = 66) were identical to
those of IGLV3-21–negative UM-CLL (n = 36) patients (SI
Appendix, Fig. S3B). Similarly, allocating the IGLV3-21R110 CLL
patients according to their IGHV mutational status and comparing the outcome revealed that M- and UM-CLL subgroup
OSs were virtually identical (SI Appendix, Fig. S3C). Additionally, 10 (45.4%) of the 22 IGLV3-21R110 CLL cases carried the
otherwise prognostically favorable del13q14 genetic abnormality
(SI Appendix, Table S8) as a standalone aberration, confirming
our previous finding with AC I (SI Appendix, Tables S2–S6). In
summary, IGLV3-21R110 has an unfavorable impact on CLL
prognosis irrespective of CLL-associated genomic aberrations
and IGHV mutational status.
As IGLV3-21 seems to be overrepresented in high-risk CLL
patients, we analyzed 90 high-risk patients from AC III (CLL2O
trial; SI Appendix, Table S9). The CLL2O sample cohort was a
multicenter, prospective phase II trial to study the efficacy of
alemtuzumab (anti-CD52 antibody) and optional allogeneic peripheral blood stem cell transplantation (allo-PBSCT) (10, 27).
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Fig. 4. IGLV3-21R110 is as severe as UM-CLL cases within a high-risk cohort
(AC III; n = 90). (A) Kaplan–Meier analysis for progression-free survival (Left)
and overall survival (Right) of IGLV3-21R110–positive CLL patients compared
with IGLV3-21R110–negative M-CLL and UM-CLL patients classified by IGHV
identity. (B) Similar Kaplan–Meier analyses as A, but for a patient who received no allogeneic PBSCT. All data are from AC III, and the depicted P
values were obtained from log-rank (Mantel–Cox) analyses.
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Presumably due to the inclusion criteria with an emphasis on
CLL with del17p and refractory TP53 mutation, only 7 cases
expressed mutated IGLV3-21R110 (7.78%) while only 1 case
expressed unmutated IGLV3-21 (SI Appendix, Fig. S4 and
Table S10). Therefore, the total IGLV3-21 frequency in AC III
was only 8.89%, but the IGLV3-21R110 CLL cases were distributed
through M-CLL (3 cases) and UM-CLL (4 cases) classification (SI
Appendix, Fig. S4) (18, 28). Similarly, different IGHV genes were
found to be effectively pairing with the IGLV3-21R110 LC and only
2 of the 7 IGLV3-21R110 cases were annotated as conventional
subset 2, confirming again that subset 2 represents only a minor
subgroup of IGLV3-21R110–expressing CLL (SI Appendix, Table
S10). Despite the low patient numbers, IGLV3-21R110 CLL patients may have progressed earlier after treatment and had inferior
OS than IGLV3-21–negative M-CLL (n = 5) within the same
cohort (Fig. 4). When restricting the analysis to patients not receiving allo-PBSCT, the outcome of the remaining 6 IGLV321R110 CLL cases was inferior compared with M-CLL in terms
of progression-free survival (PFS), possibly inferior with respect to
OS, and similar to UM-CLL (Fig. 4B).
Taken together, these results from a prospective multicenter
trial confirm that IGLV3-21R110 CLL represents a clinically aggressive group even within a select high-risk CLL cohort (AC
III), and it is solely defined by LC identity regardless of IGHV
family, mutational status, and stereotypy.
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IGLV3-21R110 Cellular Phenotype Resembles UM-CLL. Despite the

clinical aggressiveness, IGLV3-21R110–expressing CLL cases are
found within M-CLL as well as UM-CLL (Fig. 1D and SI Appendix, Fig. S1E). To further investigate the molecular mechanisms, we developed an extensive multiparametric mass cytometry
phenotyping pipeline (SI Appendix, Methods and Materials), also
known as CyTOF analyses, and investigated the cellular phenotype of IGLV3-21R110 CLL as compared with M- and UM-CLL
(SI Appendix, Table S13). For each M- and UM-CLL subgroup,
we analyzed 5 nonstereotypic CLL samples and analyzed B cells
isolated from 5 healthy donors (HDs) as control. Of note, unlike
standard cytometry analyses that measure each sample successively, we performed measurement on multiplexed samples barcoded with isotope-labeled anti–β2-microglobulin (B2M) staining
(29, 30). Indeed, the barcoding allowed robust comparative analyses between samples (SI Appendix, Fig. S5 A–C). The inclusion of
identical HD samples in each run allowed comparison between
samples from different batches.
Upon computing and analyzing the CyTOF results using
standard dimensionality reduction algorithms, we identified 17
(1 through 17) unique phenotypic clusters (Fig. 5A and SI Appendix, Fig. S5D). While the healthy B cell isolates were limited
to 3 major phenotypically discrete clusters (1 through 3), CLL
samples allocated 14 independent phenotypic clusters (4 through
17). Three HD clusters, 1 through 3, resemble major peripheral
B cell subpopulations, namely mature naïve (CD23++, CD38+,
IgM+, IgD+), immature (CD23+, CD38++, IgM++, IgD+), and
memory-like (CD23−, CD38−, IgM++, IgD+) B cells, respectively (SI Appendix, Fig. S5D).
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Expectedly, the M-CLL cells (clusters 4 through 10) were
phenotypically different from UM-CLL cells (clusters 11 through
15) and shared only 1 phenotypic cluster (cluster 5; Fig. 5 A and
B). Interestingly, the IGLV3-21R110 CLL cells shared phenotypic
clusters of both M- and UM-CLL samples (Fig. 5 B and C).
Although sharing 3 clusters from each M- and UM-CLL sample,
a closer inspection of individual IGLV3-21R110 samples revealed
that the major proportion of cells was allocated in UM-CLL
clusters (Fig. 5C and SI Appendix, Fig. S5 E and F). In addition, both IGHV-mutated (3/5) and IGHV-unmutated (2/5)
subgroups of IGLV3-21R110 cells were predominantly allocated
in UM-CLL phenotypic clusters, suggesting the expected inclination of IGLV3-21R110 CLL toward nonstereotypic UM-CLL
through shared cellular phenotype. Besides the shared phenotypic clusters, we also identified 2 unique phenotypic clusters (16,
17) of IGLV3-21R110 CLL cells. Phenotypically, these 2 clusters
possessed elevated CD23 or CD43 combined with reduced CD22
expression, which correlates with proliferating CLL cells (31).
Taken together, the phenotypic clustering analyses reveal that
the IGLV3-21R110 CLL cells are predominantly allocated in
UM-CLL classes, as expected from their similar clinical course.
IGLV3-21R110 Stimulates Autonomous Signaling. So far, the indispensable role of the IGLV3-21R110 mutation for autonomous
BCR signaling through homotypic BCR–BCR has only been
demonstrated for conventional CLL subset 2 (20). These crystallographic analyses suggested that the unique and short CDR3 in
HCs (HCDR3) of subset 2 BCR reinforces correct positioning of
LCs for mediating the BCR–BCR interaction (20). However, the
variable length and composition of HCDR3 in all CLL cases
expressing IGLV3-21R110 point to flexibility in the mutual BCR–
BCR interaction of R110-positive CLL. Therefore, we examined
the role of the R110 mutation in the BCRs derived from nonsubset 2 CLL. To analyze autonomous signaling, we expressed
BCRs derived from a non-subset 2 (sample ID: LS #83) and a
subset 2 CLL (sample ID: LS #42) using retroviral transduction of
a previously described cell line derived from RAG2, λ5, and
SLP65 triple-knockout (TKO) mice (Fig. 6A and SI Appendix, Fig.
S6A) (32, 33). In addition to BCR expression, TKO cells also
expressed an ERT2-SLP65 fusion protein for 4-hydroxytamoxifen
(4-OHT)–inducible activation of SLP65 function which allowed
robust intracellular Ca2+ release as a readout for the BCR signaling cascade (19). While the autonomously active BCRs show
rapid ligand-independent intracellular Ca2+ upon 4-OHT treatments, nonautonomous BCRs require additional ligands such as a
cognate antigen or cross-linking antibodies (34). Using this assay,
we show that the BCRs derived from both non-subset 2 (LS #83)
and subset 2 CLL (LS #42) showed autonomous signaling capacity (Fig. 6B and SI Appendix, Fig. S6B). Expectedly, reverting
IGLV3-21R110 into the IGLV3-21 LC resulted in defective autonomous signaling (SI Appendix, Fig. S6B). These data suggest
that R110 mutation boosts autonomous BCR signaling and leads
to the expansion of the respective B cells in CLL patients.

9 10 11 12 13 14 15 16 17
CLL clusters

Fig. 5. IGLV3-21R110 CLL shares cellular phenotypes of both M- and UM-CLL
cases. (A) PhenoGraph analyses of M-, UM-, and IGLV3-21R110–positive CLL
cases, all compared with peripheral B cells from HDs. Arrangement, numbering, and coloring of different phenotypic clusters from HD and M- and
UM-CLL as well as R110 cases are depicted below the PhenoGraph. For
comparison, HD clusters (1 through 3) are depicted in grayscale whereas
R110 clusters (6, 7, 10, 11, 13, and 15 through 17) are highlighted purple. (B)
Distribution and overlap of M- (black), UM- (green), and IGLV3-21R110 (red)
CLL cases in terms of cluster sharing. (C) Interleaved bar graph of the percentage of cells from M-, UM-, and IGLV3-21R110 CLL distributed into phenotypic clusters 1 through 17. Data represent the mean ± SD of 5 samples
from each of the M-, UM-, and IGLV3-21R110 CLL cases. The dashed line
represents 5% cutoff.
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The Allele IGLV3-21*01 Is a Risk Factor for IGLV3-21R110 CLL. The
crucial residues required for homotypic BCR–BCR interaction
in CLL subset 2 include residues R110 and K16 in one BCR and
D50 and D52 of the YDSD motif in a neighboring BCR (20).
Notably, the IGLV3-21 gene has 3 major alleles in humans.
Of these 3 ImMunoGeneTics (IMGT) annotated alleles of the
IGLV3-21 locus, only allele IGLV3-21*01 possesses the prerequisite K16 and YDSD motifs (SI Appendix, Fig. S7A). Indeed,
within AC I, 26 of the 27 IGLV3-21R110–positive CLL cases harbor
the allele IGLV3-21*01, suggesting that allele IGLV3-21*01 is
mechanistically required for the development of IGLV3-21R110
CLL (Fig. 7 A and B). Similarly, all subset 2 cases (n = 4) and nonsubset 2 IGLV3-21R110 CLL cases (n = 18) from AC II harbor the
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Fig. 6. CLL-derived IGLV3-21R110 LC boosts autonomous signaling. (A, Left
and Middle) BCR expression (IgM HC and Igλ LC) in TKO cells reconstituted
with CLL-derived HCs together with reverted IGLV3-21G110 (Left) or IGLV321R110 (Middle) LC variants. (A, Right) Overlaid immunophenotyping histograms
analyzing the IGLV3-21R110 expression in the same reconstituted TKO cell using
a fluorescently labeled anti-R110 antibody. (B) Exemplary Ca2+ release kinetics
of the original BCR derived from UM-CLL (LS #83) revealing autonomous BCR
signaling and containing an R110-mutated LC (IGLV3-21R110; Left) as compared
with the reverted LC containing a germline G110 (IGLV3-21G110; Right).

allele IGLV3-21*01 (SI Appendix, Fig. S7 B and C). Sequence
alignment of all IGLV3-21R110 LCs from both AC I and AC II
confirmed the prerequisite K16 residue and YDSD motif as well
as the association with allele IGLV3-21*01 (Fig. 7A and SI Appendix, Fig. S7B). In contrast, IGLV3-21–expressing CLL cases
lacking the R110 mutation harbor alleles IGLV3-21*02 or IGLV321*03 (Fig. 7B and SI Appendix, Fig. S7C).
Next, we tested if IGLV3-21R110 is exclusive to CLL B cells or
whether it exists in B cells from HDs. Based on an unbiased
sequence analysis of 41,191 rearranged IGL transcripts from 6
HDs, representing 24,288 unique LC sequences, we found that
R110 is a relatively common variant of all IGLVs except IGLV321. IGLV3-21R110 is strikingly underrepresented in HDs, with
the lowest frequency of 1/5,547 compared with all other IGLV
segments (1/17 and 1/13) and mutations at the same position
(Fig. 7 C and D and SI Appendix, Fig. S7D). Interestingly, 6 of 7
identified IGLV3-21R110 rearrangements lacked the K16 residue
essential for homotypic BCR interaction (Fig. 7E). The K16
residue was either lost by nonsynonymous SHM (3/7) or was
lacking through usage of allele IGLV3-21*02 encoding a Q16
residue. Moreover, allele IGLV3-21*03 harbors a DDSD motif
that may alter the relative positioning of the interacting D50
residue. Furthermore, we analyzed the frequency of the IGLV321R110–expressing B cell repertoire by single-cell IGV sequencing. Expectedly, only 6.38% of the sorted IGL-positive cells from
4 independent HDs expressed IGLV3-21R110 and all of them
represented either IGLV3-21*02 or IGLV3-21*03 (SI Appendix,
Fig. S7E). Together, these data suggest that the allelic variant
IGLV3-21*01 has an intrinsic potential for the generation of
BCRs with homotypic interactions and that B cells expressing the
IGLV3-21R110 variant might be counterselected in HDs.
In addition, we analyzed the occurrence of these 3 common
alleles of the IGLV3-21 gene in healthy human populations
worldwide by accessing 1000 Genomes Project data in the Ensembl
GRCh37 browser and available tools. Remarkably, the highest
frequency of the IGLV3-21*01 allele was recorded among East
Asians (EASs) as compared with Africans (AFRs), Americans
(AMRs), Europeans (EURs), and South Asians (SASs) (Fig. 7F).
Maity et al.

Moreover, detailed analyses of pertaining subpopulations revealed
that the frequencies of the IGLV3-21*01 allele among EUR
communities are similar (Fig. 7G). In contrast, the frequencies
of the IGLV3-21*01 allele among EAS subpopulations differ
among different communities and the Japanese population
sampled from Tokyo (JPT) showed the highest prevalence (Fig.
7G). In agreement with the proposed association of the allele
IGLV3-21*01 with CLL, the most frequently expressed light
chain in Japanese CLL patients is IGLV3-21 (35).
To examine whether the allele IGLV3-21*01 is required for
autonomous signaling, we engineered IGLV3-21R110 LC variants
using IGLV3-21*02 and IGLV3-21*03. Indeed, BCR containing
the IGLV3-21R110 LC matching allele IGLV3-21*02 or IGLV321*03 showed strikingly reduced autonomous signaling as compared with the original IGLV3-21*01 allele (Fig. 7H and SI
Appendix, Fig. S7F). In summary, our data demonstrate that the
allele IGLV3-21*01 represents a carrier, which enables efficient
BCR–BCR interaction and autonomous signaling upon receiving
the transforming R110 point mutation.
Taken together, our study shows that IGLV3-21R110 is frequently found in CLL because the allele IGLV3-21*01 of this
gene is particularly prone toward acquiring autonomous signaling. Unique positioning of the K16 residue and the YDSD motif
predestine the allele IGLV3-21*01 for mediating homotypic
BCR–BCR interaction upon acquiring the R110 residue. In
contrast, the allelic variants IGLV3-21*02 and IGLV3-21*03 are
underprivileged to accomplish homotypic BCR–BCR interaction
due to the lack of the prerequisite K16 and the possession of a
DDSD motif instead of the YDSD, respectively. To acquire
BCR–BCR interaction, the IGLV3-21*02 and IGLV3-21*03 alleles require several additional mutations besides the crucial
R110 (20). Consistently, the majority of the IGLV3-21R110 CLL
cases express the allele IGLV3-21*01. CLL cases expressing either the allele IGLV3-21*02 or IGLV3-21*03 might utilize alternate mechanisms for autonomous BCR signaling independent
of R110-mediated interaction. Interestingly, the R110 mutation
in HDs associates with IGLV3-21*02 or IGLV3-21*03 but not
the IGLV3-21*01 allele, suggesting that the signal-proficient,
R110-mutated, IGLV3-21*01 allele might be counterselected.
In summary, by combining structural analyses with IGLV3-21
gene sequences and signaling studies, we identify an Ig allele that
increases the risk for CLL development. We describe a scenario of
how CLL can develop through a single oncogenic driver mutation
acquired in a physiological process, namely AICDA-mediated SHM
of the IGLV3-21 gene locus.
Our data show that the unfavorable CLL subtype 2, hitherto
empirically defined by sequence characteristics of the BCR HC,
should be redefined as subtype 2L based on functional immunopathology and expanded to include all CLL expressing IGLV321R110, regardless of mutational IGHV status. Subtype 2L comprises around 20% of all CLL cases, thus representing the largest
immunologically defined CLL subtype, and carries inferior prognosis despite a high prevalence of the usually favorable del13q14.
Our monoclonal antibodies recognizing the acquired IGLV321R110 mutation will facilitate convenient recognition of subtype
2L without the necessity for sequence analysis and identification
of individuals with increased risk for developing a prognostically
unfavorable type of CLL. Furthermore, these antibodies have
the potential to develop truly CLL-specific preemptive or clinically indicated therapy that entirely spares nonmalignant B cells.
Materials and Methods
Study Populations. Analysis cohort I: Cryopreserved CLL samples (n = 154)
were obtained from the Biobank of the Department of Hematology of the
Leiden University Medical Center (LUMC) and analyzed (SI Appendix, Tables
S1–S6). Notably, complete informative follow-up data and mutational
analyses were available for 122 patients out of 154 cases in AC I.
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(blue) and allele IGLV3-21*03 (green) expressing R110. The overlay of median Ca2+ release kinetics includes a non-CLL BCR (gray) as control.

AC II: Collection of CLL cases (n = 134) expressing λLC was obtained from
the Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento
Oncologico, IRCCS and analyzed (SI Appendix, Tables S7 and S8).
AC III: CLL samples from the CLL2O trial, a multicenter phase II study of
alemtuzumab (anti-CD52 antibody) combined with dexamethasone followed
by allogeneic stem cell transplantation or alemtuzumab for maintenance (10,
27), were analyzed (SI Appendix, Tables S9 and S10). The study was approved
by institutional review boards, performed in accordance with the Declaration
of Helsinki, and registered at ClinicalTrials.gov (Identifier NCT01392079).
AC IV: CLL samples (n = 22) expressing IGLV3-21 were obtained from the
Institute of Applied Biosciences at the Centre for Research and Technology
Hellas and analyzed (SI Appendix, Table S11).
AC V: CLL samples (n = 15) expressing IGLV3-21 were obtained from the
Karches Center for Oncology Research, The Feinstein Institute for Medical
Research, Northwell Health and analyzed (SI Appendix, Table S12).
CyTOF analysis panel: CLL samples for mass cytometry (CyTOF) analyses
were obtained from the Department of Internal Medicine III, University
Hospital Ulm and analyzed (SI Appendix, Table S13).
All samples were obtained with informed consent and used in full compliance with institutional regulations. Peripheral blood mononuclear cells
from healthy donors were obtained from the Institute for Clinical Transfusion
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Medicine and Immunogenetics at Ulm University Medical Center and the
Center for Clinical Transfusion Medicine, University Medical Center Tübingen.
For deep IGLV sequence analyses, HD samples were obtained from the
Biobank, LUMC. Detailed protocols are described in SI Appendix.
Antibodies and Immunophenotyping. Detailed immunophenotyping protocol,
reagents, and antibodies are described in SI Appendix. Briefly, 100 μL of
thawed samples was washed, stained with antibody dilutions, and analyzed
by flow cytometry (BD Fortessa).
The monoclonal anti–IGVL3-21 antibodies were generated by ProteoGenix
using recombinant IgG containing a CLL subset 2-specific light chain. Both the
anti–wild-type IGLV3-21 and the anti–IGLV3-21R110 antibodies are IgG2a and Igκ.
IGV Sequencing and Annotation. Expressed IGV gene rearrangements from
CLL samples and HDs were sequenced by ARTISAN (36) and analyzed by
ImMunoGeneTics HighV-QUEST (37). Details are in SI Appendix.
Single-Cell Sorting and IGV Sequencing. CLL- and HD-derived B cells were
sorted as single cells into 384-well plates using a BD FACSAria III. After
complementary (c)DNA generation, IGHV, Ig LC Kappa variable, and IGLV
transcripts were amplified by Matrix scPCR using the specific primers and
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Mass Cytometry. Detailed mass cytometry staining protocol, reagents, and
antibodies including their origins, data acquisition, and analysis are described
in SI Appendix. Briefly, 2 × 106 cells were labeled with Pd and Pt isotopeconjugated B2M antibodies for barcoding prior to pooling (29, 30). Thereafter, the pooled samples were sequentially processed for surface staining,
fixation, and permeabilization followed by intracellular staining. Finally, the
stained cells were resuspended in Milli-Q water supplemented with EQ 4element calibration beads, filtered through a 35-μm mesh, and analyzed by
the Helios CyTOF instrument. Data were debarcoded, filtered, and gated in
FlowJo and analyzed by the open-source R-based integrated mass cytometry
analysis platform cytofkit (Bioconductor).

RT-PCR. Total RNA was isolated from healthy donors’ and UM- and M-CLL
patients’ peripheral blood mononuclear cells. cDNA was synthesized using the
High-Capacity RNA-to-cDNA Kit (Applied Biosystems). Expression of the AICDA
gene was measured using a TaqMan probe (Assay ID Hs00757808_m1; Thermo
Scientific) according to the manufacturer’s protocol.
Statistical Analysis. Data plotting and statistical analyses were performed in
Prism 7 (GraphPad) and the R software platform. Time from diagnosis to first
treatment, progression-free survival, and overall survival were obtained from
the patients’ clinical records and compared by the Kaplan–Meier method
and log-rank test. The hazard ratios of age and Rai/Binet stage at diagnosis, genetic aberrations, and BCR characteristics were calculated by Cox
proportional-hazard regression analyses. All tests were 2-sided, and statistical significance was defined as P value < 0.05.

Calcium Flux Measurement. Detailed protocols for cloning and expression of
BCRs followed by calcium flux analysis were performed as described previously (34, 40). Briefly, the IGHV and IGLV sequences obtained from the CLL
sample analyses were cloned into retroviral expression vectors for human
μHC and λLC flanked by an internal ribosomal entry sequence followed by
split-green fluorescent protein (GFP) reporters. The resulting μHC and λLC
plasmids were transfected in retroviral packaging Phoenix cell lines and the
culture medium containing the secreted virus was collected after 2 d of
transfection. Thereafter, TKO cells expressing ERT2-SLP65 were transduced
with virus supernatant by spin-infection method and GFP-expressing BCRpositive cells were analyzed after 2 to 5 d of transduction. Briefly, 2 × 106
transduced cells preloaded with the calcium-sensitive dye Indo-1 (Invitrogen)
were analyzed by flow cytometry (BD Fortessa) upon application of 2 μM
4-OHT as described (32).

Data Sharing and Detailed Protocol. In compliance with institutional regulations, all materials and experimental outcomes will be shared either by public
deposit or emails to the corresponding author. Detailed protocols associated
with different experiments are amended in SI Appendix, Methods and
Materials. Sequencing results of VDJ and annotations reported in this paper are provided in SI Appendix, Tables S1–S13.
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barcode extensions as reported previously (38), sequenced on an Illumina
MiSeq (2 × 300 bp), and analyzed by sciReptor, version v1.1-5-gaa3ec1b (39).

